Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma

Criteria:

   - Healthy participants at risk for developing melanoma and meeting the following
   criteria: must have >= 4 large (>= 5 mm and < 15 mm) atypical nevi and have 1 benign
   nevus amenable to biopsies

   - No histologically confirmed melanoma on the baseline biopsy

   - No more than 1 prior cutaneous melanoma

   - One prior stage I, IIA, or IIB melanoma allowed provided patients have been off
   treatment > 3 months

   - Modified dermoscopy score < 4.8

   - Karnofsky performance status 80-100%

   - ANC >= 1,500/mm^3

   - No family history of melanoma involving >= 2 first degree relatives

   - Platelets count >= 100,000/mm^3

   - Total bilirubin =< 2.0 mg/dL

   - AST/ALT =< 2.0 times upper limit of normal

   - Creatinine =< 1.5 mg/dL

   - Not pregnant or nursing

   - Fertile patients must use effective contraception

   - More than 6 months since prior and no concurrent tanning bed use or other methods to
   promote sun-tanning

   - Willing to minimize sunlight exposure by applying sunscreen/sunblock or wearing
   clothing to shield skin during outdoor activity during study participation

   - Willing or able to limit alcohol consumption to less than 3 servings a week during the
   study period

   - No frequent, chronic or moderate/severe gastrointestinal (GI) complaints

   - Upper GI problems requiring prescription or nonprescription medical remedies for
   symptoms of heartburn, dyspepsia, nausea, or abdominal pain > once a week on average

   - History of peptic ulcer, occult or gross intestinal bleeding

   - No prior allergic reaction to aspirin (unless subsequent dosing with other NSAIDs has
   been well tolerated)

   - No history of allergic reaction to lidocaine or xylocaine

   - No history of allergic reaction (e.g., urticaria, asthma, or rhinitis) or gastric
   intolerance attributed to compounds of similar chemical or biological composition to
   sulindac

   - No invasive cancer or cancer treatment within the past 5 years, except nonmelanoma
   skin cancer

   - No immunosuppression by medication or disease, including any of the following: AIDS,
   oral prednisone, immunosuppressant/immunomodulator (i.e., cyclosporine,
   chemotherapeutic agent, or biologic therapy)

   - No uncontrolled intercurrent illness

   - No ongoing or active infection

   - No symptomatic congestive heart failure

   - No unstable angina pectoris

   - No cardiac arrhythmia

   - No psychiatric illness/social situations that would limit compliance with study
   requirements

   - At least 30 days since prior participation and no concurrent enrollment or planning to
   enroll in another clinical trial

   - No NSAIDs for more than 5 days per month within the past 3 months and no concurrent
   non-study NSAIDs, except low dose aspirin (81 mg/day)

   - Willing or able to refrain from herbal medicines, above-standard vitamins, or minerals
   during study

   - Standard daily multivitamin/mineral supplement (i.e., therapeutic doses of calcium and
   vitamin D for osteoporosis) allowed

   - No concurrent lithium, phenytoin, or sulfonamides

   - WBC >= 3,000/mm^3

   - No history of bleeding or clotting disorder

   - At least 3 months since prior and no concurrent coumadin or other systemic
   anticoagulant other than aspirin